Timing of pharmacist‐clinician collaborative visits after hospital discharge and their effect on readmission risk

Herges, Joseph R.; Herges, Lori B.; Dierkhising, Ross A.; Mara, Kristin C.; Angstman, Kurt B.

doi:10.1002/jac5.1066

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies have discussed medications as a risk factor for hospital readmission, and some studies have examined postdischarge follow-ups with pharmacist involvement as well. 33,34 However, this study focused specifically on the impact that medication discrepancies have on readmission rates within 30 days of discharge. One study suggested that the quality of medication reconciliation may be associated with the risk of readmission.…”

Section: Discussionmentioning

confidence: 99%

A Case-Control Study: The Impact of Unintentional Discrepancies and Pharmacist Discharge Prescription Review on 30-Day Hospital Readmission

Elbeddini

Yang

Aly

2020

J Prim Care Community Health

View full text Add to dashboard Cite

Introduction: Medication discrepancies on hospital discharge are common and occur despite the use of technology to generate electronically created discharge (e-discharge) prescriptions, justifying pharmacist involvement. No published studies have focused on medication discrepancies as a risk factor for readmission. The aim was to explore the relationship between medication discrepancies on discharge and readmission rates, and how both are affected by pharmacist intervention. Objectives: The primary objective was to establish the relationship between medication discrepancies on the e-discharge prescription and hospital readmissions within 30 days of discharge. Secondary objectives were to determine the 30-day readmission rate with and without pharmacist involvement, and risk factors for 30-day readmission. Methods: This was a matched case-control study where cases and controls consisted of patients readmitted and not readmitted to hospital within 30 days of discharge from the general medicine service, respectively. Case patients were defined as patients who had been readmitted to the hospital within 30 days of discharge from the general medicine unit. Control patients were defined as patients who had not been readmitted to the hospital within 30 days of discharge. Chi-square statistics was used to analyze the association between the presence of medication discrepancy at discharge and 30-day readmission. Multivariate logistic regression was used to further analyze the associations to determine which risk factors best relate to 30-day readmission. Results: Between January 1, 2017 and December 31, 2017, a total of 401 e-discharge prescriptions were reviewed, and 194 cases were readmitted within 30 days of discharge. Similar proportions of patients were readmitted compared with not readmitted regardless of whether discrepancies were identified on the e-discharge prescriptions, and there was no relationship identified between medication discrepancies and readmission within 30 days (odds ratio [OR] = 1.04; P = .854). The readmission rate with and without pharmacist involvement was similar between the case group (50%) and control group (48.0%). The proportion of discharge prescriptions with discrepancies was 48.8% in the group that had pharmacist involvement and 47.0% in the group that had no pharmacist involvement. Additionally, a LACE score of 12 or greater was identified as a statistically significant risk factor for readmission (OR = 2.13; P < .001). Conclusions: Pharmacist review of the e-discharge prescription did not affect the readmission rate. A LACE score of 12 or greater was associated with a higher risk of readmission. Future studies are needed to identify patient groups at high risk of readmission and to determine pharmacist interventions that could reduce readmission rates.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case-Control Study: The Impact of Unintentional Discrepancies and Pharmacist Discharge Prescription Review on 30-Day Hospital Readmission

Elbeddini

Yang

Aly

2020

J Prim Care Community Health

View full text Add to dashboard Cite

show abstract

Facilitating the transfer of care from secondary to primary care: a scoping review to understand the role of pharmacists in general practice

Yahya¹,

Nazar

Huckerby³

et al. 2023

Int J Clin Pharm

View full text Add to dashboard Cite

Background Limited published research exists on the role of pharmacists in general practice (primary care pharmacists) in facilitating post-hospital discharge care of patients. Aim To summarise and map the nature and extent of current evidence on the role of primary care pharmacists in facilitating patient discharge from secondary to primary care and to inform future practice and research. Method Six electronic databases were systematically searched from inception to March 2022 for studies published in the English language that described and/or evaluated primary care pharmacist-led interventions for patients following hospital discharge. Grey literature and reference lists of included studies were also searched. Two authors independently screened articles for selection. A structured, pilot-tested form was used for data extraction. Results Twenty articles were included. The majority of studies (n = 17; 85%) were conducted in the USA. The most frequently reported intervention made by primary care pharmacists were medication reviews (n = 18) and medication reconciliation (n = 16). Studies have demonstrated the emerging roles of pharmacists involving collaboration with other healthcare professionals, review of laboratory monitoring, referrals, and follow-up. A wide range of outcomes such as the impact on hospital readmission rates, healthcare utilisation and reduction of potential adverse drug events were reported. Conclusion Pharmacists in general practice can offer a range of interventions in facilitating transfer of care of patients from secondary to primary care with positive patient and healthcare utilisation outcomes. However, more rigorous research evidence is required to establish the effectiveness, generalisability, acceptability, and sustainability of these services.

show abstract

Du développement de la pharmacie clinique en chirurgie

Airiau¹,

Blancher²,

Nivoix³

et al. 2021

Le Pharmacien Hospitalier et Clinicien

View full text Add to dashboard Cite

Timing of pharmacist‐clinician collaborative visits after hospital discharge and their effect on readmission risk

Cited by 3 publications

References 19 publications

A Case-Control Study: The Impact of Unintentional Discrepancies and Pharmacist Discharge Prescription Review on 30-Day Hospital Readmission

A Case-Control Study: The Impact of Unintentional Discrepancies and Pharmacist Discharge Prescription Review on 30-Day Hospital Readmission

Facilitating the transfer of care from secondary to primary care: a scoping review to understand the role of pharmacists in general practice

Du développement de la pharmacie clinique en chirurgie

Contact Info

Product

Resources

About